Raddeanin A is primarily studied for its potential anticancer properties. It has shown inhibitory effects on the proliferation of various cancer cell lines, including liver, breast, and colorectal cancers, by inducing apoptosis and blocking cell cycle progression. Research indicates it may suppress tumor growth through modulation of signaling pathways such as PI3K/AKT and MAPK. Additionally, Raddeanin A exhibits anti-inflammatory and antioxidant activities, which contribute to its therapeutic potential in chronic diseases. It is also being explored for its ability to enhance the efficacy of conventional chemotherapy drugs while reducing their side effects. Most applications are currently in the preclinical research stage.